Thank you so much Sophia π
17.10.2025 14:53 β π 1 π 0 π¬ 0 π 0
Beyond immune checkpoint blockade: whatβs next for #melanoma?
At #ESMO25, explore:
π Why move beyond ICB
π #AdoptiveCellTherapy
π Treating unresectable stage IV melanoma
π Bispecific T-cell engagers
π
17 Oct | 14:00β15:30
π buff.ly/RaDTAFV
16.10.2025 15:31 β π 5 π 2 π¬ 0 π 0
π ESMO is now on Bluesky
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
01.04.2025 07:36 β π 24 π 10 π¬ 3 π 4
π https://www.esmoiotech.org/article/S2590-0188(24)00034-0/fulltext
π Our review on the management of toxicities of cell therapy for solid cancers is now out in print in #ESMO βs flagship IO journal ESMO IOTECH.
π incl. TILs, TCR-T & CAR-T + associated tx e.g. IL-2 & NMA-LD.
π www.esmoiotech.org/article/S259...
@sophiawongyn.bsky.social
@fbmh-uom.bsky.social
04.01.2025 00:57 β π 11 π 4 π¬ 0 π 1
Thank you Jon!
03.01.2025 16:55 β π 1 π 0 π¬ 0 π 0
Yes definitely. A first good resolution for 2025 π
11.12.2024 14:41 β π 2 π 0 π¬ 1 π 0
So sad that you are not here!
11.12.2024 13:40 β π 1 π 0 π¬ 1 π 0
Letβs go! ππΌππΌππΌ
#CellTherapy
#TILTherapy
Welcome to π¦π¦π¦
@drbetofmdphd.bsky.social
@sklobuch.bsky.social
07.12.2024 16:13 β π 5 π 2 π¬ 0 π 0
Yay π! Our #CellTherapy for solid cancers community is growing here π¦.
Welcome π
@drbetofmdphd.bsky.social πΊπΈ
@sklobuch.bsky.social π³π±
@sophiawongyn.bsky.social πΈπ¬
#CancerImmunotherapy
07.12.2024 15:34 β π 7 π 2 π¬ 0 π 1
Signal Transduction and Targeted Therapy (STTT) | A Nature Portfolio journal | Impact Factor 52.7 | Q1 in Biochemistry, Cell Biology & Molecular Medicine | Open Access
Visit: https://www.nature.com/sigtrans/
Group leader Research Institute of Molecular Pathology (IMP) impvienna.bsky.social in Vienna, trained at MSKCC, working on #cancer #tumorimmunology #resistance. Mentor. Mum. Views are my own.
https://www.obenauflab.com/
https://www.imp.ac.at/
PhD student in the Jonkers lab |πNetherlands Cancer Institute | exploring DNA repair mechanisms and therapy resistance π§¬π
PhD student in Tissue Immunity Lab π©π»βπ¬| Champalimaud Foundation
T-cell | breast cancer | metastasis π§«
Portfolio of peer-reviewed journals from ASH including Blood, the most cited peer-reviewed publication in hematology, and Blood Advances, Blood Global Hematology, Blood ICT, Blood Neoplasia, Blood RCI, and Blood VTH https://linktr.ee/bloodjournalsportfolio
Clinician-scientist / precision medicine / cancer immunology / bioinformatics / MD, PhD
@Netherlands Cancer Institute / ESMO precision medicine working group
Trying to have fun discovering stuff to help patients.
Opinions are my own.
Officieel Bluesky account van de Universiteit Leiden. Over wetenschap, opleidingen, evenementen en studentenleven. http://universiteitleiden.nl
Editor of Technology in Cancer Research & Treatment (Impact Factor: 2.7; Q2 in Oncology - Scopus & Scimago rankings).
We use a technology-based approach to understand how our T cells recognize cancer. @nkinl.bsky.social | Tweets from lab members
Translational Immunology Research Lab at University of Minnesota Duluth.
Associate editor Science Magazine
Immunology | Haematology | Host-pathogen interactions
Post-doc at NKI-AVL - van Rheenen group - Two photon enthusiast- Vascular biologist-
Tumori Journal #TJ is an international peer-reviewed journal that publishes updates in #oncology thanks contributions by opinion leaders and emerging researchers.
#OncSky #MedSky
https://journals.sagepub.com/home/TMJ
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology communityβs work.